OVERSEA CHINESE BANKING Corp Ltd Takes $221,000 Position in DexCom, Inc. (NASDAQ:DXCM)

OVERSEA CHINESE BANKING Corp Ltd acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,297 shares of the medical device company’s stock, valued at approximately $221,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the second quarter valued at about $25,000. Sachetta LLC boosted its stake in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC acquired a new stake in shares of DexCom during the first quarter worth $29,000. Riverview Trust Co raised its stake in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC lifted its holdings in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after buying an additional 315 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Up 3.0 %

Shares of NASDAQ:DXCM opened at $74.68 on Friday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market capitalization of $29.17 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.28 and a beta of 1.17. The business has a fifty day moving average price of $69.77 and a two-hundred day moving average price of $92.14. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DXCM shares. Robert W. Baird increased their price target on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. UBS Group cut their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein upped their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Barclays reduced their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.